How to Switch from Ozempic to Mounjaro: A Complete Guide

Switching from Ozempic to Mounjaro, or from Wegovy to Zepbound, is one of the most common medication transitions in GLP-1 therapy. The reasons vary: a plateau on semaglutide, a recommendation from a doctor, or simply wanting to try the medication with stronger average weight loss data.

Here is a practical guide to how the switch works.

Why patients switch from Ozempic to Mounjaro

The most common reasons:

Weight loss plateau. Semaglutide is effective, but results often plateau at the maintenance dose. Tirzepatide's dual GIP+GLP-1 mechanism sometimes unlocks additional progress.

Stronger average results. The SURMOUNT-5 head-to-head trial (published May 2025, NEJM) compared tirzepatide with semaglutide, each at the highest dose people could tolerate, in 751 adults with obesity without type 2 diabetes. Average weight loss at 72 weeks was 20.2% with tirzepatide versus 13.7% with semaglutide (about 22.8 kg or 50 lb versus 15.0 kg or 33 lb), roughly 47% more in relative terms.

Additional indications. In the US, Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity, and since August 2026 the Mounjaro label includes reducing the risk of major cardiovascular events in adults with type 2 diabetes at high risk. Indications differ by country, so check the label where you live.

Availability and pricing. In the US, LillyDirect has offered Zepbound single-dose vials at self-pay prices (check current pricing). Zepbound is a US brand; in the UK and India, tirzepatide is sold as Mounjaro.

How the switch works clinically

Is there a washout period?

The prescribing information does not set a washout period for moving from semaglutide to tirzepatide. Many prescribers start tirzepatide on the day the next semaglutide dose would have been due, but this is a clinical decision.

Your doctor may choose to stop one medication first and monitor you briefly before starting the other. Follow their specific guidance, and do not take both medicines at the same time.

What starting dose should you use?

The labelled starting dose of tirzepatide is 2.5 mg once weekly, and the label gives no conversion from semaglutide doses. Your doctor will decide your starting dose; 2.5 mg allows your body to adjust to a new molecule.

Do not assume that because you were tolerating high-dose semaglutide (such as Ozempic 2 mg or Wegovy 2.4 mg) that you can start tirzepatide at a corresponding dose. The two drugs behave differently.

Titration after starting

Labelled Mounjaro/Zepbound dose steps (each step lasts at least 4 weeks, and you only move up if your doctor decides to):

Not everyone goes up to 15 mg. For weight management, the Zepbound label lists 5 mg, 10 mg or 15 mg as maintenance doses. Your doctor may adjust this pace depending on how you are tolerating each step.

What to expect during the transition

The first few weeks

Even patients who were well-settled on semaglutide sometimes experience a return of gastrointestinal side effects when starting tirzepatide. Nausea, mild discomfort, and reduced appetite are common in the first 2–4 weeks.

This is not a sign the medication is wrong for you, it typically settles as your body adapts. Tell your doctor if side effects are severe or do not ease.

Safety points during the switch

Get urgent medical help for severe stomach pain that does not go away (it may spread to your back, with or without vomiting), pain in the upper right abdomen with fever or yellowing of the skin or eyes, signs of a serious allergic reaction (swelling of the face, lips or throat, trouble breathing), or vomiting or diarrhoea so severe you cannot keep fluids down. If you also take insulin or a sulfonylurea, know the signs of low blood sugar, as your doses of those medicines may need adjusting. Tell your doctor about any vision changes if you have diabetic eye disease, and tell the team before any surgery or sedation. Tirzepatide carries a US boxed warning about thyroid C-cell tumours and must not be used if you or a close relative has had medullary thyroid carcinoma (MTC) or if you have MEN 2. If you use the contraceptive pill, tirzepatide can make it less reliable: the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.

Weight during transition

Weight loss may slow temporarily during the switch, particularly during the dose escalation period. This is normal. As tirzepatide reaches its therapeutic dose, weight loss typically resumes.

Appetite pattern changes

Tirzepatide's dual GIP+GLP-1 mechanism may produce a different appetite pattern than semaglutide alone. Some people describe less "hunger creep" before their next dose, but this is anecdotal and has not been shown in trials.

Ozempic to Mounjaro vs Wegovy to Zepbound

The same logic applies whether you are switching within the diabetes indications (Ozempic to Mounjaro) or within the weight management indications (Wegovy to Zepbound). Ozempic and Wegovy both contain semaglutide, and Mounjaro and Zepbound both contain tirzepatide; the brand names, doses, approved indications and availability by country differ.

Tracking the transition

When switching medications, your baseline data matters. Having a record of your weight trend, side effects, and dose history on semaglutide makes it much easier to evaluate how tirzepatide is performing relative to where you started.

Weight Easy stores your full dose history and weight trend across medication changes, so you can compare your progress before and after the switch in one view.

Final takeaway

Switching from Ozempic or Wegovy to Mounjaro or Zepbound is a common transition, and the prescribing information does not set a washout period. The labelled starting dose of tirzepatide is 2.5 mg, and your doctor decides the dose and timing. Expect a possible return of mild GI side effects during the adjustment period. In the SURMOUNT-5 head-to-head trial, tirzepatide produced more average weight loss than semaglutide, though individual results vary.

Consult your healthcare provider before making any medication changes.

Sources

• Mounjaro US prescribing information (Eli Lilly, revised August 2026): https://pi.lilly.com/us/mounjaro-uspi.pdf
• Zepbound US prescribing information (Eli Lilly, revised August 2026): https://pi.lilly.com/us/zepbound-uspi.pdf
• Wegovy US prescribing information (Novo Nordisk, revised June 2026): https://www.novo-pi.com/wegovy.pdf
• MedlinePlus — tirzepatide injection: https://medlineplus.gov/druginfo/meds/a622044.html
• Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393:26-36: https://pubmed.ncbi.nlm.nih.gov/40353578/
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022: https://pubmed.ncbi.nlm.nih.gov/35658024/

Related Articles

• Switching from Ozempic to Obeda: What to Know
• GLP-1 Weight Loss Plateau: What to Do
• New GLP-1 Drugs Pipeline 2026–2027: What's Coming